.svg){kind=logo}
Advancing Precision Medicine for IgA Nephropathy
The IgAN Atlas is an open and collaborative initiative comprised of a global team of scientists, clinicians, and patients with the aim of building an IgAN Atlas to accelerate research and ultimately enhance clinical practice, by providing the foundation to build Digital Twins of IgAN patients.
We welcome contributions of any kind from anyone interested in improving our understanding of IgAN pathogenesis and the care we deliver to people living with IgAN.
.svg){kind=logo}
.svg){kind=logo}
.svg){kind=logo}
.svg){kind=logo}
Building the IgA Nephropathy Atlas with AI technology
Our cutting-edge AI technology enables accurate identification and validation of companion biomarkers, revolutionizing precision medicine in IgA Nephropathy.
Project goals
Precision medicine offers personalized treatments for patients with IgA Nephropathy, improving outcomes and quality of life. Our AI-assisted identification and validation of companion biomarkers revolutionizes the way we approach treatment.
.svg){kind=icon}
Establish the world's largest IgAN cohort
We combine transcriptomic, clinical, and pathology data and biorepositories of blood and urine samples from several partners and external collaborators into the world’s single largest multi-modal cohort of IgAN patients.
Integrative bioinformatic analysis of transcriptomic data
Our processed transcriptomic measurements will be linked in integrated computational models, which we will use to assess the relationships among the different data sets, and to clinical parameters such as proteinuria and kidney function decline over time as well as MEST-C histopathological scores of the Oxford classification of IgAN.
Proteomic analysis of blood & urine sample and integrative bioinformatic analysis
We use Olink Explore (olink.com) to measure relative concentration of >5700 proteins in blood and urine samples from 200 IgAN patients and 80 healthy controls from biorepositories in Stockholm, Gothenburg, Nijmegen and Bari. The most promising biomarkers will be validated using a targeted approach, such as Luminex, Olink or ELISA.
Validate biomarkers in samples from a prospective clinical trial
At our clinic, we prioritize a patient-centric approach to precision medicine. We understand that each patient is unique, and we tailor our treatments to their individual needs, ensuring the best possible outcomes.
Project investigators
